Rivastigmine Oral Suspension is indicated for the following:
Symptomatic treatment of mild to moderately severe Alzheimer’s dementia.
Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson’s disease.
Summary of Product Characteristics
Read this summary of product characteristics for further information about Rivastigmine Rosemont Oral Solution. Click below to navigate to the EMC.
Patient Information Leaflet
Read this patient information leaflet about Rivastigmine Rosemont Oral Solution, what it’s used for and possible side effects. Click below to navigate to the EMC.
Rivastigmine Rosemont Oral Solution
|Click here for Audio Version
|Do not store above 30°C. Do not refrigerate or freeze
|Shelf Life (Closed Bottle/Open Bottle)
|48 months / 1 month
For further product information and pricing please use the form below and a member of the team will be in touch
Stay updated via our App
A new Rosemont Pharmaceuticals App for Healthcare Professionals is launching soon.